Akebia Therapeutics Inc
NASDAQ:AKBA
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.8567
2.24
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one AKBA stock under the Base Case scenario is 2.51 USD. Compared to the current market price of 1.88 USD, Akebia Therapeutics Inc is Undervalued by 25%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Akebia Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for AKBA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Akebia Therapeutics Inc
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Akebia Therapeutics Inc
Balance Sheet Decomposition
Akebia Therapeutics Inc
Current Assets | 100.1m |
Cash & Short-Term Investments | 34m |
Receivables | 32.2m |
Other Current Assets | 33.9m |
Non-Current Assets | 107m |
PP&E | 11.8m |
Intangibles | 68.1m |
Other Non-Current Assets | 27.1m |
Current Liabilities | 65.7m |
Accounts Payable | 13.5m |
Accrued Liabilities | 52.2m |
Non-Current Liabilities | 191.8m |
Long-Term Debt | 38.4m |
Other Non-Current Liabilities | 153.5m |
Earnings Waterfall
Akebia Therapeutics Inc
Revenue
|
169.9m
USD
|
Cost of Revenue
|
-25.8m
USD
|
Gross Profit
|
144m
USD
|
Operating Expenses
|
-176.1m
USD
|
Operating Income
|
-32m
USD
|
Other Expenses
|
-14m
USD
|
Net Income
|
-46m
USD
|
Free Cash Flow Analysis
Akebia Therapeutics Inc
USD | |
Free Cash Flow | USD |
AKBA Profitability Score
Profitability Due Diligence
Akebia Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Akebia Therapeutics Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
AKBA Solvency Score
Solvency Due Diligence
Akebia Therapeutics Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
Akebia Therapeutics Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AKBA Price Targets Summary
Akebia Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for AKBA is 5.61 USD with a low forecast of 4.04 USD and a high forecast of 7.88 USD.
Dividends
Current shareholder yield for AKBA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
AKBA Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 426 full-time employees. The company went IPO on 2014-03-20. The firm is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with dialysis-dependent (DD)-CKD or the hyperphosphatemia indication, and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis dependent (NDD)-CKD or the IDA indication. Its ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.
Officers
The intrinsic value of one AKBA stock under the Base Case scenario is 2.51 USD.
Compared to the current market price of 1.88 USD, Akebia Therapeutics Inc is Undervalued by 25%.